This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Ekso Bionics Holdings (EKSO) Stock Overview
Designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
EKSO Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ekso Bionics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.80 |
| 52 Week High | US$13.50 |
| 52 Week Low | US$2.73 |
| Beta | 0.78 |
| 1 Month Change | 25.53% |
| 3 Month Change | 30.10% |
| 1 Year Change | 65.13% |
| 3 Year Change | -49.89% |
| 5 Year Change | -84.70% |
| Change since IPO | -99.68% |
Recent News & Updates
Narrative Update • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Narrative Update • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Narrative Update • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Recent updates
Narrative Update • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Narrative Update • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Narrative Update • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Narrative Update • Mar 11
EKSO: Reverse Merger Uncertainty Will Drive Bearish Long Term Outlook
Analysts have nudged their price target on Ekso Bionics Holdings higher to $9.50 per share, reflecting updated assumptions around revenue growth, profit margin and a lower forward P/E. Together, these factors support a stronger long term valuation case at the same fair value estimate of $9.50.Narrative Update • Feb 24
EKSO: Reverse Merger And Revenue Slowdown Will Shape Cautious Outlook
Analysts have maintained their $9.50 price target on Ekso Bionics Holdings, citing only minor adjustments to inputs such as the discount rate, long term revenue growth assumptions, profit margin and future P/E that do not materially alter their valuation view. What’s in the News Applied Digital Cloud Corporation signed a letter of intent to acquire Ekso Bionics Holdings in a reverse merger, with Applied Digital expected to own about 97% of the combined company.Narrative Update • Feb 10
EKSO: Q3 Sales Recovery And Business Review Will Shape Balanced Outlook
Analysts have lifted their price target on Ekso Bionics Holdings to US$6 from US$4, citing a solid Q3 update and a company-led review of its current business as key supports for the revised valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$6 price target as a reflection of increased confidence in the company’s ability to execute on its current business plan following the Q3 update.Narrative Update • Jan 27
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 report, a newly announced review of the current business, and signs that earlier order delays may have been specific to prior periods rather than ongoing. Analyst Commentary Analysts raising their price target to $6 from $4 are reacting to the recent Q3 report and the announced review of the current business, while still flagging a few key execution risks that could affect how the story plays out from here.Narrative Update • Jan 12
EKSO: Q3 Sales Recovery And Business Review Will Support Future Upside
Analysts have lifted their fair value estimate for Ekso Bionics Holdings from $7.75 to $9.50, citing a higher Street price target of $6.00, a solid Q3 report, and the ongoing review of the current business as key reasons for the reassessment. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Ekso Bionics Holdings, with the latest price target move to US$6 framed around the recent Q3 report and the ongoing review of the current business.Narrative Update • Dec 26
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Analysts have modestly raised their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 performance and signs that earlier order delays were idiosyncratic, even as they await further confirmation that the recent sales recovery is sustainable. Analyst Commentary Bullish analysts view the higher price target as a reflection of improving execution and a clearer path to value creation following the strong Q3 report and strategic review announcement.Analysis Article • Dec 23
Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Shares Bounce 29% But Its Business Still Trails The Industry
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a really impressive month, gaining 29% after a shaky period...
Narrative Update • Dec 12
EKSO: Q3 Sales Momentum Is Expected To Drive Shares Higher
Analysts have raised their price target on Ekso Bionics Holdings to $6.00 from $4.00, citing stronger than expected Q3 sales momentum, a modestly lower perceived risk profile, and improved long term growth and profitability assumptions. Analyst Commentary Bearish analysts acknowledge that the higher price target reflects a solid Q3, but emphasize that the implied upside is increasingly reliant on sustained execution against a still-early sales recovery.Narrative Update • Nov 27
EKSO: Sales Recovery and Increased Confidence Will Drive Future Stock Performance
Analysts have raised their price target for Ekso Bionics from $6.75 to $7.75. This change reflects stronger revenue growth expectations and a solid recent earnings report.Analysis Article • Aug 24
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 26% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Narrative Update • Aug 10
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
The drastic reduction in Ekso Bionics Holdings' consensus price target from $34.75 to $6.75 reflects sharply lower growth and earnings expectations as seen in the substantial drop in its forward P/E multiple from 24.94x to 4.86x. What's in the News Launched eksoUniversity, an online platform offering CEU-approved courses for physical therapists and assistants in over 30 states.Analysis Article • Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 31% in the...Analysis Article • Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares are down a considerable 31...
New Narrative • May 01
PRIA Healthcare And National Seating Will Streamline Medicare Claims
Strategic partnerships aim to broaden distribution, streamline reimbursements, and enhance revenue growth in the personal health market.Analysis Article • Mar 07
It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 27% in the...Analysis Article • Mar 06
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), who've watched their investment drop 17% to...Analysis Article • Jan 12
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders are no doubt pleased to see that the share price has bounced...Analysis Article • Nov 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders that were waiting for something to happen have been dealt a...Analysis Article • Aug 29
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Jul 13
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a buy...Analysis Article • May 02
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
It's shaping up to be a tough period for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), which a week ago released some...Analysis Article • Dec 20
Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) is a...Analysis Article • Jun 19
Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong...Shareholder Returns
| EKSO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.8% | -5.0% | 1.2% |
| 1Y | 65.1% | -23.5% | 27.0% |
Return vs Industry: EKSO exceeded the US Medical Equipment industry which returned -18.2% over the past year.
Return vs Market: EKSO exceeded the US Market which returned 28.2% over the past year.
Price Volatility
| EKSO volatility | |
|---|---|
| EKSO Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EKSO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EKSO's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 53 | Scott Davis | www.eksobionics.com |
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation treadmill outfitted.
Ekso Bionics Holdings, Inc. Fundamentals Summary
| EKSO fundamental statistics | |
|---|---|
| Market cap | US$42.01m |
| Earnings (TTM) | -US$15.91m |
| Revenue (TTM) | US$11.57m |
3.6x
P/S Ratio-2.6x
P/E RatioIs EKSO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKSO income statement (TTM) | |
|---|---|
| Revenue | US$11.57m |
| Cost of Revenue | US$5.45m |
| Gross Profit | US$6.11m |
| Other Expenses | US$22.03m |
| Earnings | -US$15.91m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.47 |
| Gross Margin | 52.86% |
| Net Profit Margin | -137.61% |
| Debt/Equity Ratio | 67.0% |
How did EKSO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 19:08 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ekso Bionics Holdings, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Tom Grady | Edison Investment Research |
| Dan Scovel | Edison Investment Research |